People · Operator
Named in public records as an officer, director or promoter · active 2014–2025 · Biotechnology, Pharma
| Company | Role | Sector | Stage | Raised · real | Value · est | Tied |
|---|---|---|---|---|---|---|
| Juno Therapeutics, Inc. | — | Biotechnology | Growth/Late | $1.1B | $1.3B | 2014 |
| Indapta Therapeutics Inc. | — | Pharma | Series C | $84.4M | $289.9M | 2022 |
| BioEclipse Therapeutics, Inc. | — | Biotechnology | Series A | $10.1M | $366.1M | 2019 |
Mark Frohlich at the center, the companies they're named on, and every other operator named alongside them — an interlock map of shared founding teams, boards and funds. Name-matched, so treat as a research lead.
People named alongside Mark Frohlich on the same companies — an interlock signal (shared founding team, board, or fund). Name-matched, so verify before acting.
| Operator | Shared | Their companies |
|---|---|---|
| Robert Nelsen | 1 | 22 |
| Richard Klausner | 1 | 7 |
| Anthony Evnin | 1 | 6 |
| Elona Baum | 1 | 5 |
| Biao He | 1 | 5 |
| Stephen Thau | 1 | 4 |
| Ronald Martell | 1 | 4 |
| Mary Agnes Wilderotter | 1 | 3 |
| Catherine Sohn | 1 | 3 |
| Hans Bishop | 1 | 3 |
| Lori Hu | 1 | 3 |
| Gregory Schiffman | 1 | 2 |
| Rick Klausner | 1 | 2 |
| Howard J. Pien | 1 | 2 |
| Robert Azelby | 1 | 2 |
| Fabio Pucci | 1 | 2 |
| Howard Pien | 1 | 2 |
| Robert J. Nelsen | 1 | 2 |
| GUY DIPIERRO | 1 | 2 |
| Marc Tessier-Lavigne | 1 | 1 |
People are matched by normalized name across records; a common name may merge distinct individuals. Treat as a research lead, the same way modeled valuations are directional, not quoted.